Missing Script · Evidence review · October 2, 2026
“The treatment is working. But my joints hurt.”
That is a conversation worth having properly. A symptom doesn’t become small just because the scan looks good.
Tart cherry comes up as a possible way to help with joint pain during aromatase inhibitor treatment. I wanted to look at the actual trial behind that idea, rather than the much broader promises attached to cherries online.
What was tested?
A double-blind, placebo-controlled study enrolled 60 people with nonmetastatic, hormone-positive breast cancer taking an aromatase inhibitor. Forty-eight were included in the final analysis: 23 received tart cherry concentrate and 25 placebo.
Over six weeks, the reported mean percentage decrease in pain was 34.7% with tart cherry versus 1.4% with placebo (P=.034). The tested preparation was one ounce of concentrate diluted in eight ounces of water daily. This describes the study, not a recommended dose for readers.
What makes the result interesting—and uncertain?
Randomization and blinding give us a better comparison than testimonials. Still, this was small and short. Twelve enrolled participants were excluded from the final analysis: two did not complete because of diarrhea and ten were noncompliant. Missing participants can affect how we interpret the result.
The Cherry Marketing Institute funded the trial. That doesn’t invalidate it, but belongs alongside the result.
I would want a larger study that keeps track of everyone randomized and asks whether the improvement lasts. I’d also want to know whether daily tasks become easier. A pain scale matters, but so does opening a jar, taking a walk or getting through a morning without dreading movement.
The distinction the headline needs
Relieving a treatment symptom and changing the course of the cancer are different goals. This trial cannot establish that tart cherry improves treatment adherence, survival or recurrence risk. Those claims require their own evidence.
It also doesn’t tell us that a gummy, capsule, juice and concentrate are interchangeable. “Tart cherry” on a label is the beginning of a product question, not the end.
A reasonable clinic conversation
If your joints hurt, tell your oncology team rather than quietly struggling or stopping your prescribed medication. Ask what could be contributing to the pain and what options fit your situation.
If you’re interested in tart cherry, bring the exact product label. Discuss the formulation, ingredients, cost, digestive tolerability and whether its sugar content fits your dietary needs. Then ask how you would judge benefit and when to reassess. These practical questions matter even when something is familiar as a food.
- Does my situation match the people in the study?
- What other ways of managing the pain should we discuss?
- What would count as a worthwhile improvement for me?
- When should we stop or reconsider an approach that isn’t helping?
My view: this is an early finding worth discussing and testing further. It should sit inside a plan for symptom care, with realistic expectations. A small study can open a useful conversation without settling it.
Read the research
General education, not individualized medical advice. Discuss supplements and treatment decisions with your oncology team.
